Comparative Pharmacology
Head-to-head clinical analysis: INFUMORPH versus OPANA ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFUMORPH versus OPANA ER.
INFUMORPH vs OPANA ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. It mimics endogenous endorphins by binding to opioid receptors in the CNS, causing inhibition of ascending pain pathways and altering pain perception.
Opana ER (oxymorphone hydrochloride) is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action is analgesia via activation of mu-opioid receptors in the central nervous system, leading to altered perception and response to pain.
Morphine sulfate 10-30 mg orally every 4 hours as needed; or 2.5-15 mg IV/IM/SC every 2-6 hours; or 0.5-2 mg per hour continuous IV infusion. Extended-release formulations: 15-30 mg orally every 8-12 hours.
Initial: 5 mg orally every 12 hours; titrate by 5-10 mg every 12 hours every 3-7 days; maximum 40 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours in healthy adults; prolonged to 4–6 hours in the elderly or those with renal impairment, leading to accumulation of active metabolites (M6G).
Terminal elimination half-life: 11.1–13.8 hours; clinically relevant as steady-state achieved in 2–3 days
Renal elimination of morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) accounts for approximately 90% of total clearance, with <10% excreted as unchanged morphine in urine. Biliary/fecal elimination accounts for the remaining fraction (<10%).
Renal (primarily as glucuronide conjugates and unchanged drug): 85-90%; Fecal: <10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic